UroGen Pharma Announces Upcoming 2022 Conferences

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) announced its participation in two healthcare conferences in September: the H.C. Wainwright & Co. Annual Global Investment Conference on September 13 and the Ladenburg Thalmann Healthcare Conference on September 29. Both presentations will be accessible via webcasts on UroGen’s website, where replays will be available for 30 days. UroGen focuses on innovative treatments for urothelial and specialty cancers, leveraging proprietary technologies like RTGel™ for local therapies that enhance drug effectiveness.

Positive

• Participation in prominent healthcare conferences may increase visibility and investor interest.
• Development of proprietary RTGel™ technology offers potential competitive advantage in cancer treatments.

Negative

• None.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences in September:

H.C. Wainwright & Co. Annual Global Investment Conference

• Tuesday, September 13 at 10:30 a.m. ET

Ladenburg Thalmann Healthcare Conference

• Analyst Discussion on Thursday, September 29 at 8:30 a.m. ET

Webcasts of both the H.C. Wainwright & Co. and Ladenburg Thalmann presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907006069/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

UroGen Corporate Communications

cindy.romano@urogen.com

908-963-7827

Source: UroGen Pharma Ltd.

FAQ

What dates will UroGen Pharma present at the healthcare conferences?

UroGen Pharma will present at the H.C. Wainwright & Co. conference on September 13 and the Ladenburg Thalmann conference on September 29.

Where can I watch UroGen Pharma's conference presentations?

Webcasts of UroGen Pharma's presentations will be available on their website, with replays accessible for approximately 30 days.

What is UroGen Pharma's focus in the biopharmaceutical sector?

UroGen Pharma is dedicated to developing innovative solutions for treating urothelial and specialty cancers.

What technology does UroGen Pharma use in its treatment options?

UroGen Pharma utilizes RTGel™, a proprietary sustained release hydrogel technology to enhance drug delivery for cancer treatment.